Clinical Science
- 17 November 1962
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 182 (7) , 726-729
- https://doi.org/10.1001/jama.1962.03050460018005
Abstract
Hydralazine Lupus Syndrome Associated with a Possible Antihydralazine Antibody William I. Heine, M.D., and Herman Friedman, Ph.D., Philadelphia SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) is a disease thought to have a possibly hypersensitivity or immunologic basis. Patients with SLE show a spectrum of antinucleoprotein antibodies which may be detected by the LE cell test and by serological procedures.1 Attention has been called to the apparent production of SLE by an ever-increasing number of commonly used drugs.2,3 Included among these are hydralazine hydrochloride, penicillin, phenylbutazone, sulfadiazine, methylphenylethylhydantoin, trimethadione, and sulphamethothoxypyridazine. Hydralazine hydrochloride ( 1-hydrazinophthalazine) was introduced in 1951 for the treatment of hypertension. Beginning in 1954, there have been numerous reports4-10 of the occurrence of a lupuslike syndrome (hydralazine lupus syndrome) in about 10% of patients receiving hydralazine hydrochloride, usually after a year or more of daily doses exceeding 400 mg. The concept that SLE is associated with development of autoantibodiesThis publication has 0 references indexed in Scilit: